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Forced Abstinence Model of Relapse to Study Pharmacological
Treatments of Substance Use Disorder
Carmela M. Reichel and Rick A. Bevins✉
Department of Psychology, University of Nebraska-Lincoln, Lincoln NE 68588-0308
Abstract
Understanding and preventing relapse to drug use is one of the most difficult challenges faced by
clinicians and practitioners in the struggle to help people remain abstinent. In this paper, we
review basic preclinical research on forced abstinence periods that identify the neural substrates
involved and neural adaptations that occur after a drug-free period. Our attention focuses on
forced abstinence after self-administration because of its promise for translational research in the
development of candidate medications to reduce relapse. This model requires subjects (often rats)
to initially acquire drug self-administration. However, rather than extinguishing behavior with
daily drug-free sessions as in the reinstatement model of drug seeking, subjects are removed from
the self-administration situation and do not receive any exposure to the drug. Notably, the integrity
of the drug-taking behavior and the drug-associated cues in the drug-taking environment are
preserved because they are not experienced in the absence of the drug. Research shows time
dependent increases in drug-seeking following forced abstinence periods. More so, neural
substrates and adaptations within the mesocorticolimbic system and the nigrostriatal system have
been identified that contribute to increased drug seeking following abstinence. From a
translational perspective, behavioral and pharmacological treatment of substance use disorder
often starts during this initial abstinence period (either forced or voluntary). The forced abstinence
model simulates some of the features of this treatment situation and thus allows for the study of
potential treatments that alter relapse of drug-seeking behaviors along with the accompanying
neurobiological changes.
Keywords
cocaine; drug addiction; medication development; methamphetamine; reinstatement; self-
administration; drug-seeking; reward
BACKGROUND
Drug addiction is defined as a “chronic relapsing brain disease that is characterized by
compulsive drug seeking and use, despite harmful consequences” [1]. Understanding and
preventing relapse to drug use is among the most difficult problems faced by clinicians and
practitioners in the struggle to help people remain abstinent [2,3]. Indeed, the National
Institute on Drug Abuse (NIDA) reports that 40 to 60% of drug-addicted patients relapse
[1,4]. Given the high rate of relapse, there is still much room for improving treatment
approaches to substance use disorder. Such improvements that increase rates and length of
abstinence will come from theoretical and empirical advances in our understanding of the
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behavioral, neurobiological, and genetic mechanisms mediating relapse to drug use. One
way such advances will be made is through the development and refining of preclinical
animal models that capture key aspects of addiction, abstinence, and relapse. With this in
mind, the present paper will focus on the “forced abstinence” model of relapse to self-
administration behavior in rodents. As described in the following section, this underutilized
model is of much interest because it simulates several key features of an individual with
substance use disorder attempting to quit and/or receiving treatment. After a detailed
description of the forced abstinence model, we will provide an overview of what is already
understood about the behavioral and neural adaptations that occur following forced
abstinence. We will then discuss the model within a translational approach to medication
development research for the treatment of substance use disorder. Finally, throughout this
review we will suggest some possible directions for future behavioral and neurobiological
research using this model of relapse. Before discussing the forced abstinence model of
relapse, however, it will be instructive to describe the widely employed reinstatement model.
TWO MODELS OF RELAPSE
Reinstatement
In the typical reinstatement study there are 3 phases: self-administration, extinction, and
reinstatement (relapse). In the self-administration phase, subjects (often rats) prepared with
indwelling jugular catheters are trained to press a lever resulting in an intravenous (IV)
infusions of drug. As an exemplar, the left-most panel of Figure 1A shows data from our
laboratory demonstrating acquisition and maintenance of methamphetamine self-
administration. Briefly, in 1-h sessions pressing the active (drug) lever produced a 1-sec,
35.74-µl infusion of 0.05 mg/kg methamphetamine and a simultaneous 1-sec presentation of
a cue light above the active lever; pressing a second inactive lever had no programmed
consequence. To prevent accidental overdose both levers were retracted for 1 min
immediately upon earning an infusion. After 5 days of this fixed ratio (FR) 1 schedule of
reinforcement, the response requirement was increased to 3 presses per infusion on the
active lever (FR3) for 5 days and then to an FR5 for 10 days. As can be seen in the graph,
rats readily discriminated the active from the inactive lever and active lever presses
increased to match the increases in response requirement. The extinction phase of a
reinstatement experiment often commences once self-administration behavior has stabilized.
In the extinction phase, the drug-taking behavior (lever pressing in our case) and some
aspects of the drug-taking situation are presented (i.e., response contingent presentation of a
cue light, retraction of the levers, activation of the infusion pump), but the drug is no longer
available. The left panel of Figure 1A shows the extinction of active lever presses with all
experimental procedures held constant (cue-light illumination, activation of the infusion
pump, and retraction of levers) except that no methamphetamine was delivered. Responding
on the active lever fell to below 50% of that during methamphetamine self-administration
phase.
Sometime following the last extinction session (e.g., 24 h) is the primary phase of interest—
reinstatement. In the reinstatement phase, the rat is often exposed to a drug-associated
stimulus (termed cue-induced reinstatement), a challenge injection of the drug that was self-
administered (drug-induced reinstatement), or a stressor such as foot-shock (stress-induced
reinstatement). These three triggers for reinstatement are mediated by different neuronal
events and cue- and stress-induced reinstatement are sensitive to length of withdrawal
periods [5]. In all models of reinstatement, the degree to which the extinguished drug-taking
behavior re-emerges in the absence of any drug is taken as a measure of drug-seeking.
Figure 1B shows the reinstatement of active lever pressing using a within-subject drug-
primed reinstatement design. That is, rats received intraperitoneal (IP) injections of
methamphetamine (0.125, 0.25, 0.5 mg/kg) or saline 5 min before a 1-h extinction test
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session. Doses were given in an ascending order on consecutive days. As can be seen,
responding on the active lever, considered a measure of relapse to drug seeking, increased in
dose-dependent manner. In fact, the 0.5 mg/kg methamphetamine dose reinstated responding
to a pre-extinction level. This reinstatement model of drug-taking behavior has been widely
used to study the behavioral and neurobiological substrates of drug relapse. There have been
many excellent reviews of this literature [5–10], as well as published discussions of the pros
and cons of this model [e.g., 11,12]. Recapitulating these reviews and the discussion are
beyond the scope and purpose of this article. Accordingly, we refer to the reader to the cited
papers for a more detailed analysis of the reinstatement model of relapse.
Forced abstinence
For the reinstatement model of relapse just described, drug abstinence (withdrawal) begins
with the extinction phase. In the forced abstinence model, the drug abstinence period does
not involve extinction of drug-taking behaviors or the situational stimuli in which drug
taking occurs. Similar to other authors, we will use the term “forced abstinence” to describe
this scenario [cf. 13–16]. Other terms used to describe this experimental situation in the
literature include “withdrawal” or “no extinction” or “deprivation effect” [7,17–19]. In this
model of relapse, subjects acquire drug self-administration (i.e., lever pressing reinforced by
IV infusion of drug) as described previously. However, rather than extinguishing the self-
administration behavior with daily drug-free sessions, subjects are removed from the self-
administration situation for a prescribed amount of time. Thus, at the time of relapse testing
the drug-reinforced associations including lever press (i.e., drug-taking) behavior and
environmental stimuli in the self-administration situation are fully intact. As an exemplar,
Figure 2 shows the results of a recent forced abstinence experiment conducted in our
laboratory. Rats acquired methamphetamine (0.05 mg/kg/infusion) self-administration and
responding was stable for the last 7 days of training on an FR5 schedule of reinforcement
(left-most graph). Rats were then kept in their home cage in the colony room for 14 days. In
this abstinence period they were handled daily and received standard care (e.g., cage
cleaning, water change, etc.). The two 1-h relapse tests were conducted under extinction
conditions (24 h apart); identical to the earlier FR5 training except methamphetamine was
not available. After 14 days of abstinence, active lever pressing (drug seeking) on the first
extinction relapse test was comparable to the end of training (right-most panel of Figure 2).
Albeit lower, active lever pressing still persisted above that of the inactive lever on the
second relapse test.
IMPORTANT FEATURES OF FORCED ABSTINENCE MODEL
Of interest from a translational research and treatment development perspective is that this
forced abstinence model simulates some key, yet understudied, aspects of drug relapse in
humans. Whether mandated (e.g., drug court), forced (e.g., hospitalization, incarceration), or
voluntarily (e.g., check self into treatment clinic), a chronic drug user will be abstinent for
some time period before a relapse opportunity presents itself. Further, in these example
situations there is little to no opportunity for drug-taking behaviors or their associated
stimuli to be extinguished. In fact, even if someone is entering treatment, typical manualized
treatment and treatment-as-usual protocol for substance use disorder do not include forced
extinction of drug-taking behaviors or the stimuli associated with drug taking [see 20, for a
review]. As such, when these individuals are faced with a scenario that might precipitate
relapse such as running into a fellow user or coming across drug paraphernalia, the past
conditioning history with the stimuli associated with the drug and the drug-taking behaviors
are fully intact. This is a critical point considering that drug users consistently report that
exposure to drug-related stimuli (e.g., drug paraphernalia, videos of purchasing drugs, and
imagery of drug use) evoke feelings of drug craving during abstinence from cocaine,
morphine, ethanol, and nicotine [21–26]. For instance, human cocaine addicts shown
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cocaine-associated stimuli reported increased subjective feelings of craving in comparison to
conditions when non-drug neutral or arousing stimuli were viewed [27]. More so, exposure
to cocaine cues increased brain activity in sensory, motor, and cognitive-emotional
processing areas and these physiological responses were better predictors of relapse than
self-reported craving [28].
These changes in behavior, subjective states, and brain processes are thought to arise, at
least in part, from Pavlovian conditioning processes. That is, situational stimuli and
interoceptive states that occur in a contiguous manner with the nervous system effects of a
drug will enter into an association such that the stimuli acquire the ability to evoke drug-
related responses. According to this perspective, such widely used constructs as urges,
cravings, withdrawal, and seeking are conceptualized as conditioned responses evoked by
these stimuli. These conditioning processes have been given prominent roles in many
theories of addiction and are thought to be critical for acquisition and maintenance of drug-
taking behavior, as well as contributing to relapse [5,29–36]. Preclinical models that provide
a better understanding of the role of such stimuli and the behavioral, neurobiological, and
genetic mechanisms mediating their influence on relapse will be important to study because
such associative processes are active in abstaining individuals well after physiological
withdrawal from the drug. We believe that the forced abstinence model is one such tool.
BEHAVIORAL FACTORS AND FORCED ABSTINENCE
In treatment studies, a key variable used to determine success is duration of abstinence once
the intervention has started. Basic research with the forced abstinence model supports its use
as measure of treatment success. That is, the extent and degree of relapse varies as a
function of time since last drug experience. Consider the seminal work by Tran-Nguyen and
colleagues [37] demonstrating that forced abstinence periods increased cocaine seeking. In
this study, rats were trained to self-administer 0.75 mg/kg per 0.1-ml infusion of cocaine;
each infusion earned on a variable ratio (VR) 5 schedule of reinforcement was briefly
preceded by a stimulus complex consisting of a light and tone. Rats subsequently underwent
exposure to one of three differing abstinence periods: 1 day, 1 week, or 1 month. Testing
occurred after completion of the abstinence period in a 6-h test session and consisted of
extinction, cue-induced and drug-primed reinstatement tests using a within-subject and
within-session design. That is, upon return to the self-administration environment, the initial
2 h was an extinction session in which responding on the active lever was not reinforced.
The following 2 h was cue-induced reinstatement in which the light plus tone compound
stimulus previously paired with cocaine was presented independent of the rat’s behavior
(non-contingent). The final 2 h of the test assessed drug-primed reinstatement with IP
administration of 15 mg/kg cocaine. Cocaine seeking indexed as a difference between the
responses on active and inactive levers was moderately elevated after 1 month of abstinence
relative to 1 day during the extinction test and the drug-primed reinstatement test [37].
In a subsequent study, Grimm et al. [38] found that this enhanced relapse of cocaine seeking
was time dependent. In that report, rats were re-exposed to the drug-taking environment
following abstinence (1, 2, 4, 7, 15, 29, or 60 days) from cocaine using two different testing
procedures. First, rats were tested in extinction (in the manner described above). That is, rats
were able to press a cocaine-associated lever without access to drug or the stimuli previously
paired with the drug. Second, they evaluated cue-induced reinstatement of cocaine-seeking
using contingent (response dependent) presentations of the stimulus complex [cf. 38]. Both
methods of testing produced a time-dependent enhancement of cocaine-seeking behavior.
Specifically, 7 to 60 days of abstinence resulted in significantly greater responding on the
active lever in comparison to 1, 2, or 4 days of abstinence. The increase in drug seeking
following abstinence (or withdrawal) can be considered as an index of craving, defined by
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“a motivational state elicited by exposure to drug-associated cues that often precedes and
accompanies drug-seeking” (p. 215) [17]. Because enhancement requires some time post
drug self-administration to develop, this phenomenon has been termed “incubation” of drug-
associated cues [38].
Related, there is a substantial literature showing that intake of alcohol increases following a
period of forced abstinence. This alcohol deprivation effect has been suggested to model
relapse to alcohol [39]. Typically, subjects are first given chronic access to alcohol via two
(or more)-bottle choice or operant self-administration procedures [for a review see 40].
Forced abstinence follows in which alcohol is not available for a prescribed duration.
Subsequent testing allows the animal to again have access to alcohol. Intake of alcohol
increases relative to basal drinking levels. This effect has been widely replicated and
observed in rats, mice, monkeys, and humans [for a review see 40]. In contrast to the
incubation research described earlier, this model of relapse usually measures drug [alcohol]
consumption rather than persistence of a non-reinforced drug-taking behavior. Thus, the
alcohol deprivation effect is based on a measure of drug taking rather than drug seeking.
However, testing on a progressive ratio schedule of reinforcement indicates that during
periods of deprivation from alcohol rats show an increased motivation to work for alcohol
[39]. When considered together, this research supports using forced abstinence models in the
study of relapse to drug seeking.
Incubation has been observed with heroin [41], methamphetamine [42], and alcohol (i.e.,
alcohol deprivation effect, [6,39,40]. Incubation does not seem to be permanent. Rather, it
appears to follow an inverted U-shaped function. For example, heroin withdrawal impacted
drug seeking during extinction testing depending upon the length of withdrawal;
specifically, higher responding occurred on days 6, 12, or 25 but not after 1 or 66 days of
withdrawal [41]. Cocaine withdrawal results in a progressive increase in drug seeking to
cocaine-associated stimuli that peaks at 1 to 3 months but declines 6 months after
withdrawal [38,43]. Notably, the decline in cocaine seeking was only observed when
cocaine was not present; drug-primed reinstatement occurred at all time periods [43]. For
methamphetamine, time-dependent increases in extinction responding were observed at 21
and 51 days of withdrawal [42]; the descending limb of the incubation effect for
methamphetamine has not been determined.
Importantly, increased cocaine seeking following forced abstinence relies on the integrity of
the drug-paired cues being maintained during the abstinence period. A learning history that
includes extinction of drug-associated stimuli prevented increased responding for cocaine-
associated cues after a 21 day forced abstinence period [44], perhaps due to the ability of
extinction training to regulate neuroadaptations occurring during withdrawal [45]. Indeed,
direct comparisons between rats that undergo extinction training vs. forced abstinence
confirm that extinction training abolishes, whereas abstinence promotes cocaine-seeking
behavior [18,19]. In these studies, rats were first trained to press a lever on a VR5 schedule
of cocaine reinforcement (0.5 or 0.75 mg/kg per 0.1 ml, IV). Once cocaine intake stabilized,
rats were divided into extinction or forced abstinence (i.e., no extinction) groups. For the
extinction groups, extinction training began the day after self-administration training was
completed and consisted of non-contingent [18] or contingent [19] presentations of the
stimulus complex previously paired with cocaine. This training continued for 21 consecutive
daily 2-h sessions. The forced abstinence groups, on the other hand, were transported to a
different testing room and placed in an alternative environment than that in which the self-
administration training occurred. On test, both methods of extinction training (contingent
and non-contingent) eliminated cocaine-seeking behavior; forced abstinence, however,
produced a robust increase in cocaine seeking [18,19].
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Notably, incubation is not specific to drug reinforcers. Responding reinforced by sucrose
also follows time-dependent patterns with peak responding occurring at a much shorter time
interval than that of cocaine [15,17]. In brief, extinction tests allowed rats to press a sucrose-
associated lever without access to sucrose or the stimuli previously paired with the sucrose.
Under these conditions, incubation of sucrose seeking peaked after 7 days of withdrawal
then declined at 1 month to levels seen after 1 day without sucrose [17]. When re-exposed to
the stimulus complex associated with sucrose via a contingent response, sucrose seeking was
increased only at 1 month [17]. Follow-up studies designed to characterized incubation of
sucrose craving determined that shortened session lengths (i.e., 6 h reduced to 2 h) have no
impact on incubation [15]. Given that motivation engendered by sucrose or other types of
food reinforcers are subject to satiation, further tests determined whether satiation impacts
incubation. In that study, rats were allowed unlimited access to sucrose solution in their
home cages for 17 h before being placed back into the operant chambers. This sucrose pre-
loading manipulation reduced sucrose seeking on day 1 and 30 during extinction testing but
not during a test where responding produced presentation of the sucrose-paired cue. In fact,
when an active lever press resulted in a contingent presentation of the sucrose-associated cue
there were no differences in responding between rats that had 2 or 6 h session lengths or
sucrose pre-loading — all groups increased responding for the cue at 7 and 30 days post
abstinence [15]. This distinction is important because the overlap in drug and non-drug
reinforced responding for associated cues may indicate common neural networks involved in
incubation of reward seeking or craving. In fact, Grimm et al. [15] suggests “incubation of
craving may be an exaggerated expression of an adaptive behavior–exaggerated due to
neuroplastic changes mediated by the effects of high-density reward on brain reward
circuitry” (p. 78).
The ability of an abstinence period to increase drug-seeking behavior has not been
systematically characterized in regards to drug doses or reinforcement schedules. Doses
ranging from 0.2 to 0.33 mg/dose and 0.35 to 1 mg/kg per infusion of cocaine have been
used to study forced abstinence from self-administered cocaine with the most common
schedule of reinforcement being an FR1. Table 1 provides a list of experimental parameters
(e.g., cocaine dose, reinforcement schedule) from abstinence studies that have shown
enhanced cocaine seeking after a forced abstinence period. The main focus of these papers
has been on discovering the molecular mechanisms and/or neuroanatomical substrates that
contribute to increased cocaine seeking in the presence of drug-associated cues following
forced abstinence (see next section). As such, the preponderance of this research has focused
on the duration of withdrawal to define parameters in which incubation occurs; the
importance that other behavioral factors (i.e., drug dose, reinforcement schedule,
experiences during abstinence, etc.) that might contribute to the extent of relapse post-
abstinence have been left largely unexplored.
NEURAL FACTORS AND FORCED ABSTINENCE
The neurobiology of relapse has been reviewed and commented upon in detail
[9,10,17,46,47]. These reviews include coverage of the neural substrates involved in relapse
[9,10,46,47], general molecular neuroadaptations [46,48,49], or more focused reviews of the
glutamate [50] or dopamine systems [51], incubation of cocaine craving [17], or extinction
training vs. forced abstinence periods [45]. Given the number and extent of these thoughtful
and comprehensive reviews, this section will not duplicate these efforts. Instead, we will
focus on research using forced abstinence and highlight the importance of the
mesocorticolimbic circuitry and the neuroadaptations within that circuitry. We will not
discuss research that provides extinction training during the abstinence period because it
produces a different behavioral profile [18,19] and regulates neuroadaptations related to
relapse [45,52,53].
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There are two main dopamine pathways by which various drugs of abuse exert their
affective, incentive motivational, rewarding, and locomotor activating effects: the
mesocorticolimbic and the nigrostriatal systems. The latter dopamine system consists of
dopamine cell bodies located in the substantia nigra and project to the striatum (caudate/
putamen) [54,55]. The mesocorticolimbic system consists of the ventral tegmental area,
nucleus accumbens, amygdala, and prefrontal cortex. These areas interact via dopaminergic
and glutamatergic connections (see Figure 3). The connections include dopaminergic cell
bodies located in the ventral tegmental area and project to the nucleus accumbens, prefrontal
cortex, and amygdala [54–56]. Glutamatergic cortical output neurons project from the
frontal cortex to the nucleus accumbens, ventral tegmental area, and amygdala [see 57 for a
review]. The amygdala also sends glutamatergic input to the accumbens [see 58 and 50 for
reviews]. Accumbal output neurons project from the nucleus accumbens to the ventral
pallidum, and then from the ventral pallidum to the ventral tegmental area [see 59]. Many of
these brain regions have been implicated in drug seeking (especially cocaine) and there is
clear evidence of neuroadaptations in these regions when rats are re-exposed to drug-related
stimuli after a forced abstinence period.
Evidence exists from inactivation studies to implicate the involvement of both dopamine
pathways in cocaine seeking after forced abstinence. Inactivation of the dorsal lateral
caudate putamen (dlCPu) with a baclofen and muscimol (GABAA and GABAB agonists,
respectively) combination decreased cocaine seeking following 2 weeks of abstinence
[13,16]. In these experiments, rats trained to self-administer cocaine underwent 14 days of
forced abstinence. Inactivation occurred immediately before testing in a relapse condition
(i.e., the first day back in the self-administration environment). Additional extinction
sessions were conducted for 4 days. During these sessions no further differences were
apparent between inactivated and non-inactivated groups [16]. Thus, inactivation of the
dlCPu only impacted cocaine seeking on the initial relapse test. Similarly, inactivation of the
cell body regions (i.e., substantia nigra and ventral tegmental area) decreased active lever
responding on a relapse test [16]. In contrast, similar inactivation of the nucleus accumbens
core or shell had no impact on the initial relapse test but increased cocaine seeking on
ensuing abstinence tests (i.e., extinction sessions) [16]. The differences observed between
inactivation of the dlCPu and nucleus accumbens suggest that these substrates have distinct
roles in cocaine seeking following relapse. Because the striatum is more commonly
associated with habit formation, authors suggest that dlCPu may have a prominent role in
the habitual components of relapse [13,60,61]. The role of the nucleus accumbens may be to
process critical information about the relapse event because differences only emerged after
the initial relapse event occurred [16].
Changes in cell firing and multiple neuroadaptations also occur in the nucleus accumbens.
These adaptations include increased Fos expression [18,19], protein kinase A activity [62],
brain-derived neurotrophic factor [BDNF, 63], dopamine uptake [64], and expression of
glutamate receptor subunits (GluR1, GluR2, and NMDAR1) depending upon the duration of
abstinence period [62] (see Table 2). Time-dependent increases in the firing patterns of
accumbal neurons also occur after forced abstinence from cocaine [65–67].
Electrophysiology studies have identified 4 specific patterns of short duration accumbal cell
firing occurring within seconds of an operant response for cocaine that encode specific
aspects of cocaine self-administration [68,69]. One set of neurons increases firing rate
immediately before the reinforced response, whereas others increase or decrease firing rates
immediately after the completion of the response. Yet another set exhibits increased firing
immediately before and after the response with a period of inhibition in between. In regards
to abstinence, it appears that prolonged periods without the drug increases the percentage of
all 4 populations of neurons in a manner that is regionally specific to the core of the nucleus
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accumbens [67]. Combined, these studies demonstrate the importance of the nucleus
accumbens in relapse after abstinence from cocaine.
Labeling studies show Fos protein immunoreactivity is increased in cortical and subcortical
areas involved in drug reward [18,19]. Fos is the protein product of the early response gene
c-fos and is used as an index for neuronal activity because expression occurs when neurons
fire. Rats that underwent forced abstinence from cocaine for 21 consecutive days had
elevated Fos expression in the nucleus accumbens core and shell, basolateral amygdala,
dentate gyrus, hippocampal CA1, and central gray relative to extinction and control (rats that
had not received cocaine) groups [18]. A similar study replicated the observed increase in
Fos in these areas and extends this result to cortical (i.e., prelimbic, infralimbic, orbital
frontal, and anterior cingulated cortices) and limbic (i.e., dorsal caudate putamen, lateral and
central amygdala, hippocampal CA3, and dorsal hippocampus) brain regions [19]. More so,
rats that have undergone forced abstinence have an increased number Fos cells co-labeled
with AMPA glutamate receptors (i.e, GluR1, GluR2/3, and GluR4) relative to extinction and
control rats. Specifically, a greater percentage of Fos cells co-labeled with GluR1 receptors
were identified in the anterior cingulate and nucleus accumbens shell and co-labeled with
GluR5 in the infralimbic cortex. Combined these studies show the importance of regional
and subtype specificity of AMPA glutamate receptors and Fos activation in cocaine-seeking
following abstinence [19].
Other types of gene expression are changed in cortical areas following abstinence that have
demonstrated the importance of cortical involvement in regards to relapse. For example, rats
exposed to 22-h and 15-day abstinence from cocaine displayed an increase in activity-
related gene expression (e.g., c-fos, zif/268, arc, and BDNF) in the medial prefrontal, orbital
frontal cortices, and anterior cingulated cortex when re-introduced to the self-administration
environment [70,71]. More so, changes in gene expression (increased zif/268 and arc) in the
caudate/putamen and nucleus accumbens support the involvement of the cortical-striatal and
cortical-accumbens pathways in cocaine seeking after abstinence [71]. It is interesting to
note that medial prefrontal cortical inactivation did not reduce cocaine-seeking behavior
following abstinence [13], which would lead to speculation that cortical involvement may
not have a primary role in cocaine seeking following abstinence. However, inactivation of
cortical areas before testing would not circumvent molecular adaptations that occur early in
the abstinence period. That is, changes in gene expression occur as early as 22 h into the
withdrawal period, yet inactivation just before testing takes place about 2 weeks after those
neuroadaptations occur [13,70,71]. Consider the case of cortical BDNF infusions. BDNF is
a neurotrophic factor that helps to support the survival of neurons and encourages the
growth and differentiation of new neurons and synapses. When cortical BDNF infusions
occurred before a 6 day abstinence period, cocaine seeking in response to cocaine-paired
cues decreased; however, when BDNF was infused after 6 days of abstinence, cocaine
seeking was not affected [72]. Combined, these studies demonstrate involvement of cortical
pathways in relapse following abstinence periods and even more specifically suggest that
BDNF may be important for diminishing cocaine-seeking behavior early in the abstinence
period.
In fact, BDNF increases in a time-dependent manner in brain areas that receive
glutamatergic output neurons from the prefrontal cortex. That is, BDNF protein levels
progressively increased in the nucleus accumbens, ventral tegmental area, and amygdala
after 30 to 90 days abstinence from cocaine self-administration [63]–this time course
parallels that of incubation of cocaine seeking [17,38]. Given this relation between increased
BDNF and incubation, follow-up studies assessed whether infusions of BDNF into these
brain areas would increase cocaine seeking. A single infusion of BDNF into the ventral
tegmental area after the last cocaine training session potentiated cocaine seeking after 10 and
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30 days of abstinence relative to control animals [71]. Importantly, this increase was specific
to the ventral tegmental area because BDNF infusions into the substantia nigra did not
impact cocaine seeking on extinction tests. Repeated BDNF infusions into the nucleus
accumbens shell also increased cocaine seeking after forced abstinence. Specifically,
Graham and colleagues [14] injected BDNF into the nucleus accumbens shell immediately
following each cocaine self-administration session for 5 consecutive days. Rats then
underwent a 10-day forced abstinence period before being returned to the self-administration
environment for 5 days of extinction testing. BDNF treated rats had an increase in cocaine
lever pressing on the initial relapse test (i.e., the first day of extinction) that returned to
control levels on the ensuing extinction sessions. Similar infusions into the caudate/putamen
were without an effect. Combined, these findings indicate that BDNF in the
mesocorticolimbic pathway has an important role in relapse following forced abstinence, but
the precise role and the differences in cortical vs. subcortical BDNF need to be further
elucidated.
The vast majority of the research on forced abstinence has focused on cocaine. This brief
review of the neural processes clearly indicates a role for the dopaminergic and
glutamatergic pathways of the mesocorticolimbic system for cocaine seeking following
forced abstinence. Whether these findings extend to other abused substances still remains to
be determined. Such research will be critical for a better understanding of relapse, as well as
for the development of pharmacological interventions that aid in the prevention of relapse
once a user is abstinent.
USING THE FORCED ABSTINENCE MODEL TO DEVELOP
PHARMACOTHERAPIES
The research just described demonstrates that brain changes occurring during a forced
abstinence period have a profound impact on cocaine-seeking behaviors. As such, some
researchers have incorporated forced abstinence models to study mechanisms underlying
relapse [42,74,75]. In these examples, rats initially undergo drug-self administration
training, followed by a time period away from the drug-taking environment (i.e., without
extinction sessions) before being returned to the self-administration situation. The
mechanisms mediating relapse are tested by administration of a treatment drug just before
the relapse test. For instance, Gal and Gyertyan [74] investigated the importance of
dopamine D2 and D3 receptor subtypes in relapse following a 21-day abstinence period.
Initially rats were allowed to self-administer cocaine (0.25 mg/kg per infusion) for 20 days.
Following the 21 days of abstinence, separate groups of rats were injected with saline,
SB-277011 (D3 antagonist), BR-897 (D3 partial agonist/D2 antagonist), or haloperidol (D2
antagonist) before placement into the self-administration situation. All drugs reduced
cocaine-seeking (i.e., number of active lever presses) in comparison to controls, indicating a
role of both D2 and D3 receptor subtypes in relapse to cocaine seeking following abstinence.
This approach has initiated our interest in expanding the forced abstinence model for use as
preclinical screen for candidate medications for abused drugs. This approach would be
accomplished by administering a candidate medication during the forced abstinence period.
Treatment during abstinence simulates an important and common aspect of the treatment
situation that has received very little empirical attention. Whether forced or voluntarily,
chronic drug users often enter treatment to either gain or maintain abstinence. Often the
behavioral and cognitive interventions, along with any medication, start early in abstinence.
As such, assessment of potential medications (or behavioral interventions) within this time
frame may provide a valuable tool to assess efficacy of treatment compounds for addiction.
This strategy has been implemented in alcohol studies to access treatment medications
during the alcohol deprivation effect [76,77]. Such a maneuver has face validity with the
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clinical treatment situation and may serve to enhance the translational relevance of
preclinical animal tests for medications to treat substance use disorders [see References
12,17, and 39 for a critical discussion of the validity of this approach].
Very few studies exist (outside of the alcohol deprivation effect) that have administered a
treatment medication during a forced abstinence period. Those studies available provide
insight into the utility of such an approach. One recent Society for Neuroscience abstract
assessed the impact of drug treatment during a methamphetamine abstinence period [78]. In
that abstract, the maintenance self-administration schedule was an FR5 using 0.1 mg/kg/
infusion of methamphetamine. Rats were then given forced abstinence for 12 days in which
some rats were treated with 5 mg/kg of the antidepressant mirtazapine for the first 10 days
of this abstinence period. This treatment regimen decreased active lever presses when rats
were reintroduced to the self-administration situation. This finding demonstrates the
potential efficacy of mirtazapine for treating methamphetamine seeking and provides
encouraging data to further study this model within the context of medication development.
Notably, treatment efficacy may not be expressed upon return to the self-administration
situation but may occur during ensuing extinction or reinstatement periods. Such an outcome
was reported in a recent methamphetamine self-administration study. Davidson et al. [79]
trained rats to self-administer 0.1 mg/kg/infusion methamphetamine on an FR5. When
responding stabilized, rats remained in their home cages for 11 days. Treatment began on
day 3 and lasted 5 days. Rats were injected subcutaneously with either vehicle or a
pergolide/ondansetron combination. When returned to the self-administration situation
groups did not differ during the first extinction test (i.e., a measure of relapse) or on the
ensuing extinction sessions that measure the persistence of relapse-related behaviors.
Following these extinction sessions, drug-primed reinstatement was tested by systemic
injections of 0.1, 0.2, 0.3, and 0.4 mg/kg IP methamphetamine before placement into the self
administration chamber. Reinstatement tests occurred in an ascending order on consecutive
days. Drug-primed reinstatement differed between the pergolide/ondansetron and vehicle
control groups with 0.3 and 0.4 mg/kg methamphetamine reinstating drug seeking only in
the control group. Thus, pergolide/ondansetron treatment during abstinence blocked later
drug-primed reinstatement, but did not alter initial relapse when the drug-associated stimuli
and the response had yet to be experienced in the absence of methamphetamine.
Treatment during forced abstinence has also been shown to enhance relapse behavior (i.e.,
increased active lever responding). This outcome was recently reported in a cocaine self-
administration study [80]. In that study, rats were trained to self-administer cocaine (0.25
mg/infusion). Once responding stabilized on an FR1 schedule a 5 day forced abstinence
period was started. Rats remained in the colony and were treated with WIN 55,212-2, a
cannabinoid agonist, during the abstinence period. Twenty-four to 48 h after stopping
abstinence treatment, rats were reintroduced to the self-administration situation. Abstinence
treatment with the low dose of WIN 55,212-2 (0.3 mg/kg) increased active lever responses
in this relapse test; inactive lever presses were not altered. Higher doses of the cannabinoid
agonist had no effect on relapse of cocaine-seeking behavior. This type of outcome is an
important observation that suggests additional studies defining the empirical limits of such
an effect. Although this study was not focused on medication development, such a finding
with a potential medication would provide a cautionary note when considering the drug for
the treatment of relapse to substance use. Indeed, the importance of determining the
empirical limits of such and effect was demonstrated in an alcohol deprivation experiment.
Chronic naloxone was administered via osmotic mini pumps (0, 0.5, or 1 mg/kg per hour)
during a 14 day forced abstinence period [77]. Drug treatment occurred on days 10–14. This
chronic dosing regimen increased rather than decreased alcohol consumption. In contrast,
intermittent injections of naltrexone (2×5 mg/kg per day SC) reduced alcohol consumption.
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Given the research indicating the pernicious nature of chronic drug use there is a need for
the development of better treatment approaches including the use of medications to aid with
the chronic relapsing nature of drug use. The overarching goal of this review was to focus on
the behavioral and neurobiological mechanisms specific to forced abstinence (i.e.,
withdrawal) periods. Beyond this goal we wanted to emphasize studies that administer
potential medications during these forced abstinence periods. This feature simulates an
important aspect of a typical treatment situation where an individual often shows up at a
treatment facility abstinent either by force (i.e., hospitalization or incarceration) or by
choice. Findings that emerge from the basic research identifying neural substrates involved
and neural adaptations that occur during forced abstinence will inform drug development of
potential targets for treating substance abuse disorder.
Key Learning Objectives
Drug use is marked by chronic relapse despite negative consequences resulting from the
resumption of drug use. This review presents an overview of behavioral models of
relapse focusing on forced abstinence following drug self-administration. Further,
suggestions are made to expand the current model to have a more translational
perspective for medication development.
Future Research Questions
Do treatments administered during a forced abstinence period impact drug-seeking
behavior upon re-exposure to the drug taking situation? Also, what mechanisms should
be targeted for candidate medications administered during forced abstinence?
Acknowledgments
We thank Jennifer Murray for help in collecting the data and for comments on an earlier version of the manuscript.
R. A. Bevins was supported in part by a United States Public Health Service Grant DA018114 while writing this
report. C. M. Reichel was supported by DA023283 while preparing this manuscript for publication. This research
was partially funded by Promunne Inc and monies from Nebraska Tobacco Settlement Biomedical Research
Development Funds.
References
1. Drugs, Brains, and Behavior: The Science of Addiction. National Institute of Health Publication
Number 07-5605.
2. Mendelson JH, Mello NK. Management of cocaine abuse and dependence. The New England
Journal of Medicine 1996;334:965–972. [PubMed: 8596599]
3. O’Brien CP. A range of research-based pharmacotherapies for addiction. Science 1997;278:66–70.
[PubMed: 9311929]
4. McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness:
implication for treatment, insurance, and outcomes evaluation. JAMA 284:1689–1695. [PubMed:
11015800]
5. Shaham Y, Shalev U, Lu L, de Wit H, Stewart J. The reinstatement model of relapse: histroy,
methodology and major findings. Psychopharmacol 2003;168:3–20.
6. Panlilio LV, Goldberg SR. Self-administration of drugs in animals and humans as a model and an
investigative tool. Addiction 2007;102:1863–1870. [PubMed: 18031422]
7. Sanchis-Segura C, Spanagel R. Behavioural assessment of drug reinforcement and addictive
features in rodents: an overview. Addiction Biology 2006;11:2–38. [PubMed: 16759333]
8. Shalev U, Grimm JW, Shaham Y. Neurobiology of relapse to heroin and cocaine: a review.
Pharmacol Rev 2002;54:1–42. [PubMed: 11870259]
Reichel and Bevins Page 11













9. Stewart J. Pathways to relapse: the neurobiology of drug- and stress-induced relapse to drug-taking.
Journal of Psychiatry & Neuroscience 2000;25:125–136. [PubMed: 10740986]
10. Stewart, J. Pathways to relapse: Reinitiation of drug seeking after abstinence. In: Bevins, RA.;
Bardo, MT., editors. Nebraska Symposium on Motivation: Vol. 50. Motivational factors in the
etiology of drug abuse; University of Nebraska Press; Lincoln, NE. 2004. p. 197-234.
11. Epstein DH, Preston KL, Stewart J, Shaham Y. Toward a model of drug relapse: An assessment of
the validity of the reinstatement procedure. Psychopharmacol 2006;189:1–16.
12. Katz JL, Higgins ST. The validity of the reinstatement model of craving and relapse to drug use.
Psychopharmacol 2003;168:21–30.
13. Fuchs RA, Branham RK, See RE. Different neural substrates mediate cocaine seeking after
abstinence versus extinction training: A critical role for the dorsolateral caudate-putamen. J of
Neuroscience 2006;26:3584–3588.
14. Graham DL, Edwards S, Bachtell RK, DiLeone RJ, Rios M, Self DW. Dynamic BDNF activity in
nucleus accumbens with cocaine use increases self-administration and relapse. Nat Neuroscience
2007;10:1029–1037.
15. Grimm JW, Fyall AM, Osincup DP. Incubation of sucrose craving: Effects of reduced training and
sucrose pre-loading. Physiol Behav 2005;84:73–79. [PubMed: 15642609]
16. See RE, Elliott JC, Feltenstein MW. The role of dorsal vs ventral striatal pathways in cocaine-
seeking behavior after prolonged abstinence in rats. Psychopharmacol 2007;194:321–331.
17. Lu L, Grimm JW, Hope BT, Shaham Y. Incubation of cocaine craving after withdrawal: a review
of preclinical data. Neuropharmacol 2004;47:214–226.
18. Neisewander JL, Baker DA, Fuchs RA, et al. Fos protein expression and cocaine-seeking behavior
in rats after exposure to a cocaine self-administration environment. J of Neuroscience
2000;20:798–805.
19. Zavala AR, Biswas S, Harlan RE, Neisewander JL. Fos and glutamate AMPA receptor subunit
coexpression associated with cue-elicited cocaine-seeking behavior in abstinent rats. Neuroscience
2007;145:438–452. [PubMed: 17276011]
20. Ling W, Rawson R, Shoptaw S, Ling W. Management of methamphetamine abuse and
dependence. Current Psychiatry Reports 2006;8:345–354. [PubMed: 16968614]
21. Ehrman R, Robbins S, Childress A, O'Brien C. Conditioned responses to cocaine-related stimuli in
cocaine abuse patients. Psychopharmacol 1992;107:523–529.
22. Franklin TR, Wang Z, Wang J, et al. Limbic activation to cigarette smoking cues independent of
nicotine withdrawal: a perfusion fMRI study. Neuropsychopharmacol 2007;32:2301–2309.
23. Kilts CD, Schweitzer JB, Quinn CK, et al. Neural activity related to drug craving in cocaine
addiction. Archives of General Psychiatry 2001;58:334–341. [PubMed: 11296093]
24. Robbins SJ, Ehrman RN, Childress AR, O'Brien CP. Relationships among physiological and self-
report responses produced by cocaine-related cues. Addictive Behaviors 1997;22:157–167.
[PubMed: 9113211]
25. Sell LA, Morris JS, Bearn J, Frackowiak RSJ, Friston KJ, Dolan RJ. Neural responses associated
with cue evoked emotional states and heroin in opiate addicts. Drug and Alcohol Dependence
2000;60:207–216. [PubMed: 10940548]
26. Sinha R, Li CS. Imaging stress- and cue-induced drug and alcohol craving: association with relapse
and clinical implications. Drug Alcohol Rev 2007;26:25–31. [PubMed: 17364833]
27. Johnson BA, Chen YR, Schmitz J, Bordnick P, Shafer A. Cue reactivity in cocaine-dependent
subjects: effects of cue type and cue modality. Addict Behav 1998;23:7–15. [PubMed: 9468736]
28. Kosten TR, Scanley BE, Tucker KA, et al. Cue-induced brain activity changes and relapse in
cocaine-dependent patients. Neuropsychopharmacol 2006;31:644–650.
29. Anagnostaras SG, Robinson TE. Sensitization to the psychomotor stimulant effects of
amphetamine: modulation by associative learning. Behavioral Neuroscience 1996;110:1397–1414.
[PubMed: 8986341]
30. Bevins RA, Palmatier MI. Extending the role of associative learning processes in nicotine
addiction. Behavioral and Cognitive Neuroscience Reviews 2004;3:143–158. [PubMed:
15653812]
Reichel and Bevins Page 12













31. Di Chiara G. Drug addiction as dopamine-dependent associative learning disorder. E J Pharmacol
1999;375:13–30.
32. Koob, GF. Allostatic view of motivation: Implications for psychopathology. In: Bevins, RA.;
Bardo, MT., editors. Nebraska Symposium on Motivation, 50, Motivational Factors in the
Etiology of Drug Abuse; University of Nebraska Press; Lincoln. 2004. p. 1-18.
33. O’Brien CP, Childress AR, Mclellan TA, Ehrman R. Classical conditioning in drug dependent
humans. Ann. N. Y. Acad. Sci 1992;654:400–415. [PubMed: 1632593]
34. Robinson TE, Berridge KC. Incentive-sensitization and addiction. Addiction 2001;96:103–114.
[PubMed: 11177523]
35. Siegel S, Ramos BM. Applying laboratory research: drug anticipation and the treatment of drug
addiction. Exper and Clin Psychopharmacol 2002;10:162–183.
36. Wise RA. Dopamine, learning and motivation. Nat Rev Neurosci 2004;5:483–494. [PubMed:
15152198]
37. Tran-Nguyen LTL, Fuchs RA, Coffey GP, et al. Time-dependent changes in cocaine-seeking
behavior and extracellular dopamine levels in the amygdale during cocaine withdrawal.
Neuropsychopharmacol 1998;19:48–59.
38. Grimm JW, Hope BT, Wise RA, Shaham Y. Incubation of cocaine craving after withdrawal.
Nature 2001;412:141. [PubMed: 11449260]
39. Spanagel R, Holter SM. Pharmacological validation of a new animal model of alcoholism. J Neural
Trans 2000;107:669–680.
40. Le AD, Shaham Y. Neurobiology of relapse to alcohol in rats. Pharmacol. Ther 2002;94:137–156.
[PubMed: 12191599]
41. Shalev U, Morales M, Hope B, Yap J, Shaham Y. Time-dependent changes in extinction behavior
and stress-induced reinstatement of drug seeking following withdrawal from heroin in rats.
Psychopharmacol 2001;156:98–107.
42. Shepard JD, Bossert JM, Liu SY, Shaham. The anxiogenic drug yohimbine reinstates
methamphetamine seeking in a rat model of drug relapse. Biol Psychiatry 2004;55:1082–1089.
[PubMed: 15158427]
43. Lu L, Grimm JW, Dempsey J, Shaham Y. Cocaine seeking over extended withdrawal periods:
Different time courses of responding induced by cocaine cues versus cocaine priming over the first
6 months. Psychopharmacol 2004;176:101–108.
44. Di Ciano P, Everitt BJ. Reinstatement and spontaneous recovery of cocaine-seeking following
extinction and different durations of withdrawal. Behav Pharmacol 2002;13:397–405. [PubMed:
12394416]
45. Self DW, Choi KH, Simmons D, Walker JR, Smajula CS. Extinction training regulates
neuroadaptive responses to withdrawal from chronic cocaine self-administration. Learning
Memory 2004;11:648–657. [PubMed: 15466321]
46. Rebec GV, Sun WL. Neuronal substrates of relapse to cocaine-seeking behavior: role of prefrontal
cortex. J Exp Analysis Behav 2005;84:653–666.
47. See RE. Neural substrates of cocaine-cue associations that trigger relapse. Europ J Pharmacol
2005;526:140–146.
48. Shaham Y, Hope BT. The role of neuroadaptations in relapse to drug seeking. Nat Neuroscience
2005;8:1437–1439.
49. Thomas MJ, Kalivas PW, Shaham Y. Neuroplasticity in the mesolimbic dopamine system and
cocaine addiction. British J Pharmacol 2008;154:327–342.
50. Kalivas PW. Glutamate systems in cocaine addiction. Curr Opin Pharmacol 2004;4:23–29.
[PubMed: 15018835]
51. Self DW. Regulation of drug-taking and -seeking behaviors by neuroadaptations in the mesolimbic
dopamine system. Neuropharmacol 2004;47:242–255.
52. Schmidt EF, Sutton MA, Schad CA, et al. Extinction training regulates tyrosine hydroxylase
during withdrawal from cocaine self administration. J Neuroscience 2001;21:1–5.
53. Sutton MA, Schmidt EF, Choi KH, et al. Extinction-induced upregulation in AMPA receptors
reduces cocaine-seeking behaviour. Nature 2003;421:70–75. [PubMed: 12511956]
Reichel and Bevins Page 13













54. Fallon JH. Topographic organization of ascending dopaminergic projections. Ann NY Acad Sci
1988;537:216–227. [PubMed: 3059925]
55. Ungerstedt U. Stereotaxic mapping of the monoamine pathways in the rat brain. Acta Physiologica
Scandinavica 1971;367:1–48.
56. Oades RD, Halliday GM. Ventral tegmental (A10) system: neurobiology. 1. Anatomy and
connectivity. Brain Res 1987;434:117–165. [PubMed: 3107759]
57. Tzschentke TM. Pharmacology and behavioral pharmacology of the mesocortical dopamine
system. Prog Nerurobiol 2001;63:241–320.
58. Baker, DA.; Cornish, JL.; Kalivas, PW. Glutamate and dopamine interactions in the motive circuit.
In: Herman, BH., editor. Glutamate and Addiction. Totowa NJ: Humana Press; 2003. p. 143-156.
59. Kalivas PW, Churchill L, Romanides A. Involvement of the pallidal-thalamocortical circuit in
adaptive behavior. Ann NY Acad Sci 1999;877:64–70. [PubMed: 10415643]
60. Faure A, Haberland U, Conde F, El Massioui N. Lesion to the nigrostriatal dopamine system
disrupts stimulus-response habit formation. J Neuroscience 2005:2771–2780.
61. Jog MS, Kubota Y, Connolly CI, Hillegaart V, Graybiel AM. Building neural representations of
habits. Science 1999;286:1745–1749. [PubMed: 10576743]
62. Lu L, Grimm JW, Shaham Y, Hope BT. Molecular neuroadaptations in the accumbens and ventral
tegmental area during the first 90 days of forced abstinence from cocaine self-administration in
rats. J Neurochemistry 2003;86:1604–1613.
63. Grimm JW, Lu L, Hayashi T, Hope BT, Su TP, Shaham Y. Time-dependent increases in brain-
derived neurotrophic factor protein levels within the mesolimbic dopamine system after
withdrawal from cocaine: Implications for incubation of cocaine craving. J Neuroscience
2003;23:742–747.
64. Samuvel DJ, Jayanthi LD, Manohar S, Kaliyaperumal K, See RE, Ramamoorthy S. Dysregulation
of dopamine transporter trafficking and function after abstinence from cocaine self-administration
in rats: Evidence for differential regulation in caudate putamen and nucleus accumbens. J
Pharmacol Exper Therap 2008;325:293–301. [PubMed: 18198344]
65. Ghitza UE, Fabbricatore AT, Prokopenko V, Pawlak AP, West MO. Persistent cue-evoked activity
of accumbens neurons after prolonged abstinence from self-administered cocaine. J Neuroscience
2003;23:7239–7245.
66. Hollander JA, Carelli RM. Abstinence from cocaine self-administration heightens neural encoding
of goal-directed behaviors in the accumbens. Neuropsychopharmacol 2005;30:1464–1474.
67. Hollander JA, Carelli RM. Cocaine-associated stimuli increase cocaine seeking and activate
accumbens core neurons after abstinence. J Neuroscience 2007;27:3535–3539.
68. Carelli RM, Deadwyler SA. A comparison of nucleus accumbens neuronal firing patterns during
cocaine self-administration and water reinforcement in rats. J Neuroscience 1994;14:7735–7746.
69. Carelli RM, Deadwyler SA. Cellular mechanisms underlying reinforcement-related processing in
the nucleus accumbens: electrophysiological studies in behaving animals. Pharmacology,
Biochemistry, and Behavior 1997;57:495–504.
70. Hearing MC, Miller SW, See RE, McGinty. Relapse to cocaine seeking increases activity-
regulated gene expression differentially in the prefrontal cortex of abstinent rats. Psychopharmacol
2008;198:77–91.
71. Hearing MC, See RE, McGinty JF. Relapse to cocaine-seeking increases activity-regulated gene
expression differentially in the striatum and cerebral cortex of rats following short or long periods
of abstinence. Brain Struct Funct. 2008 May 17; Epub ahead of print.
72. Berglind WJ, See RE, Fuchs RA, et al. A BDNF infusion into the medial prefrontal cortex
suppresses cocaine seeking in rats. Europ J Neurosci 2007;26:757–766.
73. Lu L, Dempsey J, Liu SY, Bossert JM, Shaham Y. A single infusion of brain-derived neurotrophic
factor into the ventral tegmental area induces long-lasing potentiation of cocaine seeking after
withdrawal. J Neurosci 2004;24:1604–1611. [PubMed: 14973246]
74. Gal K, Gyertyan I. Dopamine D3 as well as D2 receptor ligands attenuate the cue-induced cocaine-
seeking in a relapse model in rats. Drug Alcoh Depend 2006;81:63–70.
Reichel and Bevins Page 14













75. Lu L, Uejina JL, Gray SM, Bossert JM, Shaham Y. Systemic and central amygdala injections of
the mGluR2/3 agonist LY379268 attenuate the expression of incubation of cocaine craving. Biol
Psychiatry 2007;61:591–598. [PubMed: 16893525]
76. Heyser CJ, Moc K, Koob GF. Effects of naltrexone alone and in combination with acamprosate on
the alcohol deprivation effect in rats. Neuropsychopharmacol 2003;28:1463–1471.
77. Holter SM, Spanagel R. Effects of opiate antagonist treatment on the alcohol deprivation effect in
long-term ethanol-experienced rats. Psychopharmacol 1999;145:360–369.
78. Fox, RG.; Dhonnchadha, NIC.; Cunningham, KA.; Specio, SE.; Napier, T. Program No. 813.14.
2007 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience; 2007. Self-
administration of methamphetamine: reduction in drug-seeking during forced abstinence following
repeated mirtazapine treatment. Online
79. Davidson CD, Gopalan R, Ahn C, et al. Reduction in methamphetamine induced sensitization and
reinstatement after combined pergolide plus ondansetron treatment during withdrawal. Europ J
Neuroscience 2007;565:113–118.
80. González-Cuevas G, Aujla H, Martin-Fardon R, López-Moreno JA, Navarro M, Weiss F.
Subchronic cannabinoid agonist (WIN 55,212-2) treatment during cocaine abstinence alters
subsequent cocaine seeking behavior. Neuropsychopharmacol 2007;32:2260–2266.
Reichel and Bevins Page 15














This figure shows active and inactive lever presses (Mean ± SEM) for rats (n= 14) trained to
self-administer 0.05 mg/kg/infusion methamphetamine. Panel A depicts the acquisition of
the lever press response on FR 1, 3, and 5 schedules of reinforcement and the extinction of
such a response. Panel B illustrates drug-primed reinstatement tested with 0, 0.125, 0.25,
and 0.5 mg/kg methamphetamine IP.
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This figure shows active and inactive lever presses (Mean ± SEM) for rats (n=10) trained to
self-administer 0.05 mg/kg/infusion methamphetamine. Following stable methamphetamine
self-administration (last 7 days of drug access are shown), rats were given 14 days of forced
abstinence followed by 2 consecutive relapse tests occurring 24 hr apart. These tests were
conducted with contingent presentations of the stimulus complex on an FR5 schedule of
reinforcement.
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This figure is a schematic representation of the mesocorticolimbic and nigrostriatal systems
that are important in relapse to cocaine seeking following abstinence. Abbreviations: NAC,
nucleus accumbens; STR, striatum (caudate and putamen); GP, globus pallidus; SN,
substantia nigra; VTA, ventral tegmental area.
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Table 1
Overview of experimental parameters in forced abstinence studies with cocaine




Behavioral test(s) following forced abstinence
Fuchs et al., 2006 [13] 0.2 mg/dose FR1 14 days Extinction – responding on active lever had no
scheduled consequence
Berglind et al., 2007 [72] 0.2 mg/dose FR1 22 h & 6 days Extinction – contingent presentation of stimulus
complex
Gal & Gyertyan, 2007 [74] 0.25 mg/dose FR1 3 weeks Extinction – contingent presentation of stimulus
complex
Hollander & Carelli, 2005
[66]
0.33 mg/dose FR1 1 day & 1 month Extinction – responding on active lever had no
scheduled
Drug-primed reinstatement
Hollander & Carelli, 2007
[67]
0.33 mg/dose FR1 1 day & 1 month Extinction – contingent presentations of
stimulus complex
Ghitza et al., 2003 [65] 0.35 mg/kg/inf FR1 3–4 weeks Extinction – presentation of a tone discriminitive
stimulus
Neisewander et al., 2000
[18]
0.5 mg/kg/inf VR5 21 days Extinction – non-contingent presentation of
stimulus complex
Grimm et al., 2001[38] 0.5 mg/kg/inf FR1 1, 2, 4, 7, 15, 29,
& 60 days
Extinction – responding on active lever had no
scheduled consequence
Extinction – contingent presentation of stimulus
complex
Graham et al., 2007 [14] 0.5 mg/kg/inf FR5 10 days Extinction – responding on active lever had no
scheduled consequence
Hearing et al., 2008 [70] 0.6 mg/kg/inf FR1 22 h & 15 days Extinction – responding on active lever had no
scheduled consequence
See et al., 2007 [16] 0.6 mg/kg/inf FR1 14 days Extinction – responding on active lever had no
scheduled consequence
Zavala et al., 2007 [19] 0.75 mg/kg/inf VR5 22 days Extinction – contingent presentation of stimulus
complex
Tran-Nguyen et al., 1989
[37]
0.75 mg/kg/inf VR5 1 day, 1 week, &
1 month
Extinction – responding on active lever had no
scheduled consequence
Cue-induced reinstatement – non-contingent
presentation of stimulus complex
Drug-primed reinstatement
Lu et al., 2007 [75] 0.75 mg/kg/inf FR1 3 & 21 days Extinction – contingent presentation of stimulus
complex
Lu et al., 2004 [43] 1.0 mg/kg/inf FR1 24 h, 1, 3, & 6 months Extinction – contingent presentation of stimulus
complex
Drug-primed reinstatement
Grimm et al., 2003 [63] 1.0 mg/kg/inf FR1 1, 30, & 90 days Extinction – responding on active lever had no
scheduled consequence
Cue-induced reinstatement – contingent
presentation of stimulus complex
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Table 2
Overview of abstinence related brain changes from forced abstinence studies with cocaine
Reference Cocaine dose Abstinence period Abstinence related brain changes
Cortex
Hearing et al., 2008 [71] 0.6 mg/kg/inf 22 h & 15 days Anterior cingulate – increased zif/268 and c-fos at 22 h and 15 days,
increased Arc mRNA at 22 h
Hearing et al., 2008 [70] 0.6 mg/kg/inf 22 h & 15 days Dorsomedial PFC – increased c-fos, zif/268, arc, and BDNF (BDNF only
increased when drug
associated lever was available) at 22 h, all were increased at 15 days of
abstinence
Orbital frontal – increased c-fos, zif/268, arc, and BDNF at 22 h and 15
days
Neisewander et al., 2000
[18]
0.5 mg/kg/inf 21 days Increased Fos in anterior cingulate
Zavala et al., 2007 [19] 0.75 mg/kg/inf 22 days Increased Fos in prelimbic, infralimbic, orbital frontal, and anterior
cigulate; increased percentage of
Fos cells colabeled with GluR1 in anterior cigulate; and co-labled GluR5
in infralimbic cortex
Amygdala
Tran-Nguyen et al., 1989
[37]
0.75 mg/kg/inf 1 day, 1 week, &
1 month
Increased basal and extracellular dopamine concentrations following 1
month abstinence
Grimm et al., 2003 [63] 1.0 mg/kg/inf 1, 30, & 90 days Increased BDNF but not NGFat 30 and 90 days
Neisewander et al., 2000
[18]
0.5 mg/kg/inf 21 days Increased Fos in basolateral amygdala
Nucleus Accumbens
Samuvel et al., 2008 [64] 0.6 mg/kg/inf 21 days Increased dopamine uptake
Hearing et al., 2008 [71] 0.6 mg/kg/inf 22 h & 14 days Increased zif/268 and Arc mRNA at 22 h and 15 days abstinence
Lu et al., 2003 [62] 1 mg/kg/inf 1, 30, or 90 days Increases GluR1 and NMDAR1 on days 1 and 90, increased GluR2 levels
on days 1 and 30
Grimm et al., 2003 [63] 1.0 mg/kg/inf 1, 30, & 90 days Increased BDNF but not NGFat 30 and 90 days
Neisewander et al., 2000
[18]
0.5 mg/kg/inf 21 days Increased Fos in core and shell
Zavala et al., 2007 [19] 0.75 mg/kg/inf 22 days Increased Fos in core and shell; increased percentage of
Fos co-labled with GluR1 in core
Caudate Putamen
Samuvel et al., 2008 [64] 0.6 mg/kg/inf 21 days Increased dopamine uptake, increased surface expression of dopamine
transporter, decreased
intracellular levels
Hearing et al., 2008 [71] 0.6 mg/kg/inf 22 h & 14 days Increased zif/268 and Arc mRNA at 22 h and 15 days abstinence
Zavala et al., 2007 [19] 0.75 mg/kg/inf 22 days Increased Fos in dorsal lateral caudate putamen
Ventral Tegmental Area
Lu et al., 2003 [62] 1 mg/kg/inf 1, 30, or 90 days Increases NMDAR1 on days 1, 30 and 90, increased GluR2, TH, Cdk5
levels on day 1
Grimm et al., 2003 [63] 1.0 mg/kg/inf 1, 30, & 90 days Increased BDNF but not NGFat 30 and 90 days
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